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Alzheimer’s disease pathology is closely connected to the processing of the amyloid precursor protein (APP)
resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble aggregates in
senile plaques, the histopathological hallmark of the disease. These peptides are also found in soluble, mostly
monomeric and dimeric, forms in the interstitial and cerebrospinal fluid. Due to the combination of several
enzymatic activities during APP processing, Aβ peptides exist in multiple isoforms possessing different N-termini
and C-termini. These peptides include, to a certain extent, part of the juxtamembrane and transmembrane domain
of APP. Besides differences in size, post-translational modifications of Aβ – including oxidation, phosphorylation,
nitration, racemization, isomerization, pyroglutamylation, and glycosylation – generate a plethora of peptides with
different physiological and pathological properties that may modulate disease progression.Introduction
Since its identification from senile plaques, amyloid-beta
(Aβ) peptide has been considered to play a central role in
the pathology of Alzheimer’s disease (AD) [1]. Aβ is
thought to accumulate in AD cases because of an imbal-
ance in the production and clearance of this peptide
resulting in the formation of the characteristic amyloid
plaques in specific brain regions. The large majority of AD
cases are of sporadic nature, showing inefficient removal
of Aβ [2], whereas a minority of cases is caused by genetic
mutations (familial AD) with an onset typically below age
65 years. Most of these cases are caused by autosomal
dominant mutations in genes related to the processing of
amyloid precursor protein (APP) leading to increased pro-
duction of Aβ.
To generate Aβ from APP, the precursor has to be
cleaved by a set of two proteases (Figure 1). The first
cleavage occurs at a luminal, juxtamembrane position,
resulting in the formation of a membrane-bound
C-terminal stub that, in a subsequent step, is cleaved by
an unconventional protease complex, called γ-secretase,
within the transmembrane domain, thereby liberating Aβ.
Both cleavages have been shown to be imprecise. β-site
amyloid precursor protein cleaving enzyme 1 (BACE1),
the enzyme that conducts the initial processing,
step-cleaves APP at a minimum of two positions, whereas* Correspondence: markus.kummer@ukb.uni-bonn.de
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2014γ-secretase generates a variety of different Aβs spanning
34 to 50 amino acids in length.
Most AD cases are sporadic, however, without changes
in the production of the Aβ peptide. The propensity to
form aggregates and toxic species may therefore be driven
by factors other than changes in the production of certain
Aβ peptides. Several post-translational modifications
(PTMs) have been discovered that on the whole increase
the aggregation rate of Aβ (Figure 2). Some of these modi-
fications, such as oxidation and nitration, are obviously in-
duced by the inflammatory milieu that is a component of
AD [3].
PTMs can function as a molecular switch to evoke cel-
lular responses, but one should consider that they may
also be a result of protein aging that is random and
without any physiological impact.
Truncated amyloid-beta species
Amyloid-beta species generated by α-secretase,
β-secretase, and γ-secretase
Three enzymatic activities are involved in APP process-
ing, and were named α-secretase, β-secretase, and
γ-secretase at a time when their molecular identities
were unknown. APP exists in several isoforms ranging
from 695 to 770 amino acids in length, including the do-
main from which the Aβ peptide derives. In APP695
(the most abundant isoform in the brain) this domain
ranges from amino acids 597 to 638. In an initial step,
APP is cleaved at a juxtamembrane position at the lu-
minal side of the membrane. This cleavage is mediatedCentral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain

















Figure 1 Generation of different amyloid-beta domain-derived peptides from the amyloid precursor protein. The amyloid precursor
protein (APP) is preferentially cleaved in the non-amyloidogenic pathway by α-secretase into a large ectodomain called sAPPα, and into a
C-terminal stub called α-C-terminal fragment (α-CTF), which is further processed by γ-secretase into p3 peptides. Alternatively, APP may be
cleaved in the amyloidogenic pathway by β-secretase into an ectodomain called sAPPβ and into a longer C-terminal stub called β-C-terminal
fragment (β-CTF). This stub is preferentially cleaved by γ-secretase to generate amyloid-beta (Aβ) peptides, but some β-CTF precursors are cleaved
by α-secretase resulting in C-terminal truncated Aβ species.
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in different compartments of the cell [4]. The majority of
APP molecules in non-neuronal cells are initially cleaved
by α-secretase between positions 16 and 17 of the Aβ
domain. This is the so-called non-amyloidogenic pathway
since the cleavage occurs within the Aβ domain, thereby
preventing the production of Aβ. This event generates a
stub called α-C-terminal fragment as well as a large ecto-
domain called sAPPα. Several members of the ADAM
family of proteases are able to mediate this cleavage, but
in neurons this function is likely to be exerted by the con-
stitutively active ADAM10 protease [5].
In the amyloidogenic pathway, leading to the produc-
tion of Aβ peptides, β-secretase mediates the initial rate-
limiting step. The membrane-bound aspartyl-protease
BACE1 has been identified as the responsible enzyme.
APP is cleaved by this enzyme before position 1 of the
Aβ domain [6], resulting in the release of a large ectodo-
main and the formation of a stub called β-C-terminal
fragment. In addition, BACE1 can also cleave APP
within the Aβ domain between positions 10 and 11 (β′
site) [7]. Subsequently, both N-terminally cleaved pre-
cursors are further processed by γ-secretase, a complex
that consists of at least the proteins APH-1, PEN-2,nicastrin and presenilin 1 or presenilin 2 [8]. The trans-
membrane proteins presenilin 1 and presenilin 2 possess
two critical aspartyl residues that are part of the catalytic
domain of this γ-secretase subunit. The cleavage occurs
within the transmembrane domain of APP, generating
C-terminally truncated peptides ending with amino acids
37 to 43, due to an imprecise cleavage of these enzymes.
The resulting peptides are liberated into extracellular
fluids such as cerebrospinal fluid (CSF), plasma or inter-
stitial fluid. This phenomenon is not fully understood,
but endoproteolysis is thought to occur stepwise, cleav-
ing the C-terminal stubs several times within their trans-
membrane domain. These cleavages are approximately
three amino acids apart [9,10]: one at amino acid 48 or
49, followed by another one at position 45 or 46, and
ending with a final cleavage most often at position 38,
40 or 42. At least in the CSF of nondemented controls,
about one-half of the Aβ ends at amino acid 40, 16%
ends at amino acid 38, and 10% ends at amino acid 42
[11]. Aβ species ending with the alanine at position 42
have a stronger tendency to aggregate as compared with
Aβ1–40. These species are thought to be the driving fac-
tor for the formation of amyloid plaques and the neuro-




























































Figure 2 Positions of post-translational modifications in
amyloid-beta 1–42. Blue letters indicate amino acid residues that
are subject to post-translational modifications (PTM). Multiple PTM
have been observed for some amino acid (aa) residues.
Aβ, amyloid-beta.
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and 43 [9]. There are even shorter Aβ isoforms (Aβ1–
17/18/19/20) that depend on γ-secretase [13,14] but the
precise mechanism of their generation is unknown.
Both processing pathways lead to a large variety of
peptides that start either at position 1 or position 11
caused by cleavage by BACE1 or at position 17 mediated
by α-secretase. The latter peptides are called p3 [15] but
are not found in senile plaques, and neither do they yet
appear to have any pathological or physiological role.
Most of these N-terminal starting points are found in
combination with the heterogeneity caused by the cleav-
age of γ-secretase.To make things even more complicated, the amyloido-
genic pathway and the nonamyloidogenic pathway seem
not to be mutually exclusive. There are shorter isoforms
of Aβ (Aβ1–14/15/16) present in the CSF that do not
depend on γ-secretase cleavage but are sensitive to in-
hibitors of α-secretase. Interestingly, Aβ1–14/15/16 in-
crease after γ-secretase treatment in CSF [16,17]. This
leads to the conclusion that C-terminal BACE1-cleaved
stubs (C99) are not exclusive substrates for γ-secretase,
and that C99 can reach compartments with α-secretase
activity resulting in the liberation of Aβ1–14/15/16
along alternative pathways [13,14,18].
N-terminal amyloid-beta truncations independent of α-
secretase or β-secretase
There are several N-terminal truncations observed in
AD that cannot be explained by the action of the above-
described enzymes [19]. In general, N-terminal trunca-
tions make up the majority of Aβ species in AD [20,21]
but not in the transgenic mice mouse model, which
might explain the differences in the molecular mecha-
nisms of amyloid deposition [20,22]. In addition, the
shortening of the N-terminus increases the propensity of
Aβ to form aggregates in vitro [23]. Since Aβ is degraded
by several secretory proteases, such as insulin-degrading
enzyme and neprilysin among others [24], it is possible
that truncations arise from these enzymes.
The 2-x Aβ species has been found to be increased in
the brains of AD patients [25,26] and decreased in the
CSF of AD patients [27]. There was a suggestion that this
species might derive from the combined action of BACE1
followed by aminopeptidase A [25]. Recently, the metallo-
protease meprin-beta was reported to initially shed APP
in a BACE1-independent fashion, releasing different Aβ
species with several cleavage sites. These sites are reported
to be identical with or proximal to the known β-secretase
cleavage site [28], and overexpression of meprin-beta gen-
erates Aβ2–40 [11,25]. However, further studies and ap-
propriate mouse models are necessary to investigate the
contribution of meprin-beta in AD.
The 3-x Aβ species has been detected in a mouse
model of AD [20,29,30] and in senile plaques from
brains of late AD cases [31]. It has been suggested that
this species is generated by Cu2+-mediated amide hy-
drolysis or the peptide bond between amino acids 2 and
3 of Aβ [32].
One of the first Aβ peptides reported was the N-
terminal truncated 4-x species [33]. In comparison with
other species, Aβ4–42 was found to be relatively abun-
dant in AD and vascular dementia [34]. In vivo, mice
overexpressing Aβ4–42 suffer from a massive CA1 pyr-
amidal neuronal loss, accompanied by memory dysfunc-
tion [35]. There is so far no candidate enzyme that
mediates this cleavage.
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pressing an APP lacking the C-terminal 31 amino acids,
but has also been discovered in AD patients using a 5-x
Aβ neo-epitope antibody [36,37] and in nondemented
controls by mass spectometry [21]. Interestingly, using
APP-overexpressing cell lines, inhibition of BACE1 re-
sulted in the appearance of Aβ5–40 [38,39]. This species
has also been detected in the 5XFAD mouse model of
AD [29] and in the CSF of dogs treated with BACE1 in-
hibitor [39].
The largest amino truncations, aside from that at pos-
ition 11 mediated by BACE1, are so far the cleavages
that occur before amino acids 7, 8 and 9 observed in the
brains of AD patients [21,22]. A candidate enzyme for
the formation of the 8-x Aβ species might be
angiotensin-converting enzyme [40], but so far there are
no in vivo data supporting this pathway.
Amyloid-beta species modified by post-
translational modification
Oxidation
The most prominent site of oxidative changes within Aβ
is the methionine at position 35 (Met35). Increased oxi-
dative stress has been described in the brains of mild
cognitive impaired and AD patients. Part of this oxida-
tive stress is mediated by the Aβ peptide itself, but other
mechanisms, such as inflammatory inducers and others,
may also be relevant.
Oxidation of Met35 to methionine sulfoxide in AD
was first observed years ago [41]. The reaction proceeds
through a radical intermediate that can be prevented by
the use of radical scavengers [42]. Several studies dem-
onstrated that oxidation of Met35 impedes the forma-
tion of Aβ protofibrils and fibrils from monomers
[43,44]. A role for Met35-oxidized Aβ in the formation
of ion-channel-like structures in lipid membranes has
also been reported [45].
Phosphorylation
In theory, Aβ possesses three potential phosphorylation
sites at serine residues 8 and 26 and at tyrosine residue
10. There are numerous examples of phosphorylated
extracellular/luminal protein suggesting the existence of
extracellular kinases that facilitate this PTM. Phosphor-
ylation of the serine at position 26 has been described in
NT2 neurons and AD brains [46]. In vitro, this PTM is
generated by the action of the cdc2 kinase. In turn, using
a cdc2 kinase inhibitor, the neurotoxic effect of Aβ on
NT-2 neurons can be reduced [46].
Phosphorylation of Aβ at serine 8 has been studied in
more detail. Using phospho-serine-8-specific Aβ anti-
bodies revealed the presence of phosphorylated Aβ in
AD mouse models and AD. Under pathological condi-
tions this species was found to be localized to amyloidplaques [47], but could also be found intracellularly [48].
Biophysically, this PTM increases the formation of oligo-
meric Aβ aggregates that represent nuclei for fibrilliza-
tion. This species shows increased toxicity in drosophila
models as compared with nonphosphorylated Aβ [47].
In addition, serine 8-phosphorylated Aβ is resistant to
degradation by insulin degrading enzyme [49].
Nitric-oxide-caused modifications
Nitric oxide (NO) induces several PTMs, including the
formation of S-nitrothiols at cysteine residues and nitra-
tion and dityrosine formation at tyrosine residues [50].
Increased presence of these NO-caused PTMs has been
observed in AD [51,52]. The source of NO during AD is
most probably the enzyme NOS2, which is upregulated
in AD [53,54]. As a molecular target, tyrosine 10 of Aβ
has been shown to increase the propensity of Aβ to ag-
gregate and has been identified in the core of the amyl-
oid plaques [55]. The reaction of Aβ with peroxynitrite,
an intermediate NO product, in vitro has been shown to
generate both nitrated Aβ and dityrosine-coupled Aβ.
The latter modification could also be detected in the
core of amyloid plaques [55] and may stabilize Aβ di-
mers [56]. Nitrated Aβ was able to initiate plaque forma-
tion in APP/PS1 mice, suggesting a central role during
the early phase of AD [55]. Hippocampal long-term po-
tentiation was suppressed more by nitrated Aβ com-
pared with non-nitrated Aβ. This demonstrates that this
PTM is involved in both the functional and structural
changes in AD. In addition, formation of this Aβ species
is favored by oxidative stress [56,57].
Glycosylations
Mass spectrometry analysis of controls and AD patients
revealed the presence of O-glycosylated Aβ species in
CSF [58]. The glycoforms included monosialylated, disia-
lylated, and trisialylated modifications, as well as lactone
modifications. The exact molecular nature of the glyco-
sylation has not been determined and could therefore be
GlcNAc, GalNAc, or ManNAc in either α-linkage or β-
linkage to the conjugated amino acid. Glycosylation oc-
curred on Aβ1–15/16/17/18/19/20, Aβ3–15, Aβ4–15,
Aβ4–17, and Aβ5–17 peptides, with Aβ1–15 and Aβ1–
17 peptides being the most abundant of all Aβ1–X gly-
copeptides. The absolute concentration for glycosylated
Aβ1–15 was calculated to be 10 to 30 pg/ml CSF,
whereas that for unglycosylated Aβ1–15 ranged from
100 to 200 pg/ml. For Aβ1–15 and Aβ1–17 the glycosyl-
ations were selectively attached to tyrosine 10 of the Aβ
sequence. The lack of glycosylated Aβ1-40/42 peptides
in CSF led to the conclusion that tyrosine 10 O-
glycosylation in APP modifies the γ-secretase cleavage,
because of the proximity of this glycosylation to the
transmembrane domain [58].
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The initial attempts to identity the N-terminus of Aβ re-
vealed a minor species beginning with glutamic acid at
position 3 [59]. Development of specific antibodies to
pyroglutamate Aβ demonstrated its weak solubility and
presence in amyloid plaques [60]. As an initial step, for-
mation of pyroglutamate-modified Aβ at position 3
(3pE-Aβ) requires the removal of the first two amino
acids from Aβ. Aminopeptidase A has been suggested as
an enzyme facilitating this processing [61], but this has
yet to be proven. In addition, spontaneous amide hy-
drolysis by Cu2+ has been reported [32]. Further, another
pyroglutamate modification at aspartate 11 was discov-
ered (11pE-Aβ) [41,62]. This species may arise from the
alternative BACE1 cleavage side in APP [63,64]. In a
subsequent step, the terminal glutamate is converted to
a pyroglutamate in a dehydration reaction. This reaction
can be catalyzed by the enzyme glutaminyl cyclase [65],
which is increased in AD [66]. Reduction of glutaminyl
cyclase results in reduced formation of pyroglutamate
Aβ in vitro [67] and in vivo [66,68]. Further, reduced
glutaminyl cyclase expression in AD mouse models is
accompanied by reductions in Aβ40/42 levels, reduced
plaque burden, inflammatory reaction, and improved
memory and spatial learning [66,68].
In vitro, 3pE-Aβ42 has a similar toxicological profile
on neuronal cells to that of Aβ1–42 [69], which was
confirmed by intracerebroventricular injections of either
3pE-Aβ42 or Aβ1–42 [70]. Like many changes in the N-
terminus of Aβ, 3pE-Aβ and 11pE-Aβ show increased
propensity to aggregate and to form β-sheets in vitro.
This may be caused by higher hydrophobicity since two
charges are lost during conversion [71]. pE-Aβ has been
detected in a variety of AD mouse models, yet the time
of first appearance during pathology varies strongly be-
tween different mouse models – ranging from 2 months
in the APP/PS1KI model [72], to 16 months in the
Tg2576 model [73], to 15 months in the APP23 model
[20]. Interestingly, there has been extensive neurotoxicity
described in mouse models that generate pyroglutamate-
modified Aβ [74,75].
Isomerization
Peptides are susceptible to spontaneous, non-enzymatic
isomerization particularly at asparagine and aspartate
residues, resulting in the formation of isoaspartate.
These aspartyl-bond isomerizations affect the secondary
structure of the peptide and may therefore be critical for
the development of pathological processes such as ag-
gregation and deposition [76]. In parenchymal plaque
core preparations, the predominant species of Aβ at the
aspartyl residues 1 and 7 is the L-isoaspartyl form [77].
Interestingly, the amount of isoaspartyl residues in Aβ
preparations from vascular depositions is lowercompared with preparations from senile plaques [77,78],
suggesting that Aβ from plaques are older since this
PTM increases over the lifetime. Isomerization of aspar-
tate 23 has not so far been detected by biochemical
means in AD brains.
In vitro, substitutions of positions 1, 7 and 23 of Aβ by
isoaspartate increased the tendency of these peptides to
form β-pleated sheets [78], to form aggregates [79,80]
and to contribute to the enhanced insolubility and resist-
ance to enzymatic degradation [81]. The presence of
isoaspartate-7 Aβ detected by specific antibodies was
suggested to be an indicator of plaque age since this was
found mostly in the core of amyloid plaques and corre-
lated with dementia severity [82].
Racemization
Racemization is the process of conversion of enantio-
mers so that both enantiomers are present. In the case
of amino acids this is the conversion from the L-form to
the D-form, especially at seryl and aspartyl residues.
Presence of D-enantiomers of aspartyl and seryl residues
in Aβ have long been described [83-85]. As for isomer-
ized Aβ, the presence of racemized aspartyl residues in
Aβ was found to be higher in amyloid plaques compared
with vascular Aβ [77]. In vitro, racemization of Aβ can
be induced by radicals [86]. In a recent study, the en-
richment of D-Asp1 as well as of its isomer D-isoAsp1
could be demonstrated in the tissue of AD patients by
mass spectometry [87]. D-Ser26-Aβ1–40 possesses a
stronger tendency to form fibrils [84].
Use of amyloid-beta species as diagnostic marker
and as a target for treatment
Because of its disease-dependent regulation in the CSF,
Aβ has been used as a biomarker for AD. In particular, the
concentration of Aβ1–42 in the CSF undergoes a charac-
teristic drop during disease progression, which is inter-
preted as the consequence of the ongoing parenchymal
Aβ deposition in senile plaques. In addition, the CSF levels
of Aβ1–40 remain constant so that the ratio of Aβ1–42/
Aβ1–40 is a valuable predictor. Since the C-terminal trun-
cated Aβ1–14/15 species are elevated after inhibition of γ-
secretase, their use as a readout for trials aiming at the
modulation of γ-secretase has been suggested [88]. The
sensitivity can be increased by combining the markers
Aβ1–42, Aβ1–38 and pTau, resulting in a 94% discrimin-
ation between nondemented patients and AD patients
[89]. Beyond the diagnosis of AD, the concentration of
Aβ1–38 is specifically lowered in the CSF of patients af-
fected by fronto-temperal dementia [90].
The search for human auto-antibodies in plasma and
CSF revealed that most antibodies recognized either
oligomeric or post-translationally modified Aβ [91], sug-
gesting that this species might be a relevant target for
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whether unmodified Aβ has a physiological role, there is
a certain risk that preventive immunotherapy may cause
undesirable effects. In addition, decreased levels of Aβ
autoantibodies might even contribute to disease progres-
sion as has been shown for pyroglutamate-modified Aβ
[92]. The immunotherapy directed at pathological Aβ
species is therefore a road that should be followed.
Several PTMs of Aβ increase the tendency of Aβ to
aggregate [46,57,91] and are found in the core of amyl-
oid plaques [55,93], suggesting that plaque formation de-
pends on them. The use of inhibitors that interfere with
their formation therefore has to be evaluated. In particu-
lar, inhibitors for glutaminyl cyclase [66], the relevant ki-
nases for the phosphorylation of Aβ and NO-producing
enzymes, especially NOS2 [55], should be tested as a
therapeutic option.
Conclusion
From the plethora of Aβ species, some are generated
very early during APP processing, some are modified im-
mediately afterwards, or others are found or generated
in certain cellular or extracellular compartments, and
some are actually markers for the slow to non-existent
turnover of these peptides in amyloid plaques. Certain
regions of Aβ obviously contribute differentially to its
properties, like N-terminal truncations, and certain
amino acids are hotspots for PTMs. There is a possibility
that some of these species might serve as excellent diag-
nostic markers or therapeutic targets in the future.
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